Impax Asset Management Group plc Has $3.53 Million Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Impax Asset Management Group plc decreased its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 1.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 8,549 shares of the company’s stock after selling 106 shares during the period. Impax Asset Management Group plc’s holdings in IDEXX Laboratories were worth $3,534,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. FSA Wealth Management LLC bought a new position in IDEXX Laboratories in the 3rd quarter valued at approximately $25,000. E Fund Management Hong Kong Co. Ltd. lifted its stake in IDEXX Laboratories by 5,700.0% in the 3rd quarter. E Fund Management Hong Kong Co. Ltd. now owns 58 shares of the company’s stock valued at $29,000 after purchasing an additional 57 shares during the last quarter. Retirement Wealth Solutions LLC bought a new position in IDEXX Laboratories in the 4th quarter valued at approximately $31,000. Ashton Thomas Securities LLC bought a new position in IDEXX Laboratories in the 3rd quarter valued at approximately $37,000. Finally, Kestra Investment Management LLC bought a new position in IDEXX Laboratories in the 4th quarter valued at approximately $38,000. Institutional investors own 87.84% of the company’s stock.

Wall Street Analyst Weigh In

IDXX has been the subject of several research reports. Bank of America increased their price objective on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the company a “neutral” rating in a research note on Tuesday, February 4th. Barclays increased their price objective on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the company an “overweight” rating in a research note on Tuesday, February 4th. Morgan Stanley dropped their price target on shares of IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating for the company in a research note on Wednesday, January 29th. Piper Sandler raised their price target on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the company a “neutral” rating in a research note on Monday, February 10th. Finally, Leerink Partners started coverage on shares of IDEXX Laboratories in a research note on Monday, December 2nd. They set an “outperform” rating and a $500.00 price target for the company. Four equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, IDEXX Laboratories has an average rating of “Moderate Buy” and a consensus price target of $533.75.

Insiders Place Their Bets

In other news, Director M Anne Szostak sold 3,000 shares of IDEXX Laboratories stock in a transaction dated Friday, February 7th. The shares were sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the completion of the transaction, the director now directly owns 3,061 shares in the company, valued at $1,426,242.34. This trade represents a 49.50 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Sophie V. Vandebroek sold 344 shares of IDEXX Laboratories stock in a transaction dated Wednesday, November 27th. The shares were sold at an average price of $420.44, for a total transaction of $144,631.36. Following the transaction, the director now owns 905 shares of the company’s stock, valued at $380,498.20. This represents a 27.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 13,330 shares of company stock worth $6,161,276. 2.11% of the stock is currently owned by company insiders.

IDEXX Laboratories Trading Up 2.4 %

IDXX opened at $463.66 on Tuesday. IDEXX Laboratories, Inc. has a twelve month low of $398.50 and a twelve month high of $583.39. The company has a quick ratio of 0.95, a current ratio of 1.31 and a debt-to-equity ratio of 0.28. The company has a fifty day moving average of $432.58 and a 200-day moving average of $452.04. The stock has a market cap of $37.97 billion, a PE ratio of 43.45, a price-to-earnings-growth ratio of 3.41 and a beta of 1.37.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.